Publications

2024

Symmetric Consistency with Cross-Domain Mixup for Cross-Modality Cardiac SegmentationCai Z, Xin J, Dong S, Onofrey J, Zheng N, Duncan J. Symmetric Consistency with Cross-Domain Mixup for Cross-Modality Cardiac Segmentation. 2024, 1536-1540. DOI: 10.1109/icassp48485.2024.10447304.
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Einstein D, Catalano P, Hammers H, Regan M. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal For ImmunoTherapy Of Cancer 2024, 12: e008293. PMID: 38604810, PMCID: PMC11015345, DOI: 10.1136/jitc-2023-008293.
Abstract 5673: Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinomaMeli K, Ricker C, Camp S, Smith C, Labaki C, Saad E, Soulati H, Reardon B, Park J, Vokes N, Vincent B, Choueiri T, Braun D, Van Allen E. Abstract 5673: Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinoma. Cancer Research 2024, 84: 5673-5673. DOI: 10.1158/1538-7445.am2024-5673.
Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell CarcinomaHan S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRISundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative studyLokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.
Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy HistopathologyZeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
Reply by AuthorsSterling J, Simhan J, Flynn B, Rusilko P, França W, Ramirez E, Angulo J, Martins F, Patel H, Higgins M, Swerdloff D, Nikolavsky D. Reply by Authors. Journal Of Urology 2024, 211: 607-607. PMID: 38382012, DOI: 10.1097/ju.0000000000003888.
(121) Utilizing ChatGPT for Urology Trainee Simulation of Peyronie’s Disease CounselingReddy S, Smani S, Honig S, Harnisch B, Rotker K. (121) Utilizing ChatGPT for Urology Trainee Simulation of Peyronie’s Disease Counseling. The Journal Of Sexual Medicine 2024, 21: qdae001.115. DOI: 10.1093/jsxmed/qdae001.115.
(013) How do Sexual Medicine Specialists Handle Patient Counseling and Penile Rehabilitation in Patients Undergoing Robotic Assisted Radical Prostatectomy (ralp): Trends in Pre Op and Post Operative ManagementHeckscher D, Honig S, Rotker K. (013) How do Sexual Medicine Specialists Handle Patient Counseling and Penile Rehabilitation in Patients Undergoing Robotic Assisted Radical Prostatectomy (ralp): Trends in Pre Op and Post Operative Management. The Journal Of Sexual Medicine 2024, 21: qdae001.011. DOI: 10.1093/jsxmed/qdae001.011.
(376) High Capability of ChatGPT to Answer Common Patient Questions on Vasectomy Reviewed by Sexual Medicine SpecialistsReddy S, Harnisch B, Honig S, Rotker K. (376) High Capability of ChatGPT to Answer Common Patient Questions on Vasectomy Reviewed by Sexual Medicine Specialists. The Journal Of Sexual Medicine 2024, 21: qdae001.361. DOI: 10.1093/jsxmed/qdae001.361.
Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical ProstatectomyKim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical Prostatectomy. Prostate International 2024 DOI: 10.1016/j.prnil.2024.01.002.
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).Aragon-Ching J, Petrylak D, Sridhar S, Gupta S, Grivas P, Powles T, Gurney H, Jacob N, Tyroller K, Guenther S, Bellmunt J. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI). Journal Of Clinical Oncology 2024, 42: 600-600. DOI: 10.1200/jco.2024.42.4_suppl.600.
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.Cheng H, Callis S, Lin D, Yu E, Dorff T, Kase A, Tangen C, Petrylak D, Lerner S. SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations. Journal Of Clinical Oncology 2024, 42: tps354-tps354. DOI: 10.1200/jco.2024.42.4_suppl.tps354.
Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.Saliby R, Xie W, Wells J, Saad E, Eid M, Labaki C, Semaan K, Ferrier E, Lemelin A, Suárez C, Ruiz-Morales J, Powles T, Wood L, Ebrahimi H, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study. Journal Of Clinical Oncology 2024, 42: 400-400. DOI: 10.1200/jco.2024.42.4_suppl.400.
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.El Ahmar N, Matar S, Jegede O, Nabil Laimon Y, Savla V, Bagheri Sheshdeh A, Denize T, Mohanna R, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2024, 42: 448-448. DOI: 10.1200/jco.2024.42.4_suppl.448.
Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.Semaan K, El Zarif T, Seo J, Eid M, Canniff J, Fortunato B, Savignano H, Davidsohn M, Lakshminarayanan G, Saad E, Saliby R, Bakouny Z, Matar S, Nuzzo P, Berchuck J, Signoretti S, Braun D, Freedman M, Baca S, Choueiri T. Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation. Journal Of Clinical Oncology 2024, 42: 449-449. DOI: 10.1200/jco.2024.42.4_suppl.449.
Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.Saad E, Labaki C, Miron B, Park J, Bakouny Z, Nassar A, Saliby R, Semaan K, Eid M, Meli K, Nabil Laimon Y, Geynisman D, Kokate R, Braun D, Signoretti S, McGregor B, Plimack E, Choueiri T, Van Allen E, Zibelman M. Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 459-459. DOI: 10.1200/jco.2024.42.4_suppl.459.
Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).Serzan M, Jegede O, Bilen M, Braun D, Einstein D, Haas N, Hammers H, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Choueiri T, Signoretti S, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps492-tps492. DOI: 10.1200/jco.2024.42.4_suppl.tps492.
Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic StenosisSterling J, Simhan J, Flynn B, Rusilko P, França W, Ramirez E, Angulo J, Martins F, Patel H, Higgins M, Swerdloff D, Nikolavsky D. Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic Stenosis. Journal Of Urology 2024, 211: 596-604. PMID: 38275201, DOI: 10.1097/ju.0000000000003848.
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.Grivas P, Pouessel D, Park C, Barthelemy P, Bupathi M, Petrylak D, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis N, Recio-Boiles A, Sternberg C, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa S, Loriot Y. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. Journal Of Clinical Oncology 2024, jco2202835. PMID: 38261969, DOI: 10.1200/jco.22.02835.
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesLoriot Y, Petrylak D, Kalebasty A, Fléchon A, Jain R, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar A, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa S. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals Of Oncology 2024, 35: 392-401. PMID: 38244927, DOI: 10.1016/j.annonc.2024.01.002.
Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse modelWang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomicsGross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 1-10. PMID: 38217704, DOI: 10.1007/s00330-023-10495-5.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.Milowsky M, O'Donnell P, Hoimes C, Petrylak D, Flaig T, Moon H, Friedlander T, Mar N, McKay R, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret A, Yu Y, Dillon R, Kataria R, Beaumont J, Purnajo I, Rosenberg J. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal Of Clinical Oncology 2024, jco2301547. PMID: 38215355, DOI: 10.1200/jco.23.01547.
Patient-Specific Heart Geometry Modeling for Solid Biomechanics Using Deep LearningPak D, Liu M, Kim T, Liang L, Caballero A, Onofrey J, Ahn S, Xu Y, McKay R, Sun W, Gleason R, Duncan J. Patient-Specific Heart Geometry Modeling for Solid Biomechanics Using Deep Learning. IEEE Transactions On Medical Imaging 2024, 43: 203-215. PMID: 37432807, PMCID: PMC10764002, DOI: 10.1109/tmi.2023.3294128.
Association Between Maternal Depression and Lower Urinary Tract Symptoms in Their Primary School-Age DaughtersCunningham S, Lindberg S, Joinson C, Shoham D, Chu H, Newman D, Epperson N, Brubaker L, Low L, Camenga D, LaCoursiere D, Meister M, Kenton K, Sutcliffe S, Markland A, Gahagan S, Coyne-Beasley T, Berry A, Brubaker L, Mueller E, Acevedo-Alvarez M, Fitzgerald C, Hardacker C, Hebert-Beirne J, Lavender M, Shoham D, Kenton K, Griffith J, Simon M, Geynisman-Tan J, Markland A, Coyne-Beasley T, Burgio K, Lewis C, McGwin G, Vaughan C, Williams B, Lukacz E, Gahagan S, LaCoursiere D, Nodora J, Miller J, Low L, Harlow B, Rudser K, Brady S, Chu H, Fok C, Scal P, Rockwood T, Lindberg S, Newman D, Smith A, Berry A, Bilger A, Klusaritz H, Lipman T, Stapleton A, Wyman J, Sutcliffe S, James A, Lowder J, Meister M, Rickey L, Camenga D, Cunningham S, Brubaker L, Barthold J. Association Between Maternal Depression and Lower Urinary Tract Symptoms in Their Primary School-Age Daughters. Journal Of Wound Ostomy And Continence Nursing 2024, 51: 53-60. PMID: 38215298, PMCID: PMC10794027, DOI: 10.1097/won.0000000000001039.

2023

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell CarcinomaChoueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
Unsupervised Domain Adaptation by Cross-Prototype Contrastive Learning for Medical Image SegmentationCai Z, Xin J, Dong S, You C, Shi P, Zeng T, Zhang J, Onofrey J, Zheng N, Duncan J. Unsupervised Domain Adaptation by Cross-Prototype Contrastive Learning for Medical Image Segmentation. 2023, 00: 819-824. DOI: 10.1109/bibm58861.2023.10386055.
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.
Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional StudyMarks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaPetrylak D, Eigl B, George S, Heath E, Hotte S, Chism D, Nabell L, Picus J, Cheng S, Appleman L, Sonpavde G, Morgans A, Pourhosseini P, Wu R, Standley L, Croitoru R, Yu E. Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research 2023, 30: of1-of11. PMID: 37861407, PMCID: PMC10767306, DOI: 10.1158/1078-0432.ccr-22-3627.
LiverHccSeg: A publicly available multiphasic MRI dataset with liver and HCC tumor segmentations and inter-rater agreement analysisGross M, Arora S, Huber S, Kücükkaya A, Onofrey J. LiverHccSeg: A publicly available multiphasic MRI dataset with liver and HCC tumor segmentations and inter-rater agreement analysis. Data In Brief 2023, 51: 109662. PMID: 37869619, PMCID: PMC10587725, DOI: 10.1016/j.dib.2023.109662.
Trends in new and persistent opioid use in older adults with and without cancerBaum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.
Cross-Attention for Improved Motion Correction in Brain PETCai Z, Zeng T, Lieffrig E, Zhang J, Chen F, Toyonaga T, You C, Xin J, Zheng N, Lu Y, Duncan J, Onofrey J. Cross-Attention for Improved Motion Correction in Brain PET. 2023, 14312: 34-45. PMID: 38174216, PMCID: PMC10758996, DOI: 10.1007/978-3-031-44858-4_4.
Fast Reconstruction for Deep Learning PET Head Motion CorrectionZeng T, Zhang J, Lieffrig E, Cai Z, Chen F, You C, Naganawa M, Lu Y, Onofrey J. Fast Reconstruction for Deep Learning PET Head Motion Correction. 2023, 14229: 710-719. PMID: 38174207, PMCID: PMC10758999, DOI: 10.1007/978-3-031-43999-5_67.
HIGH CAPABILITY OF CHATGPT TO ANSWER COMMON PATIENT QUESTIONS ENCOUNTERED BY REPRODUCTIVE UROLOGISTSReddy S, Rotker K, Honig S, Harnisch B. HIGH CAPABILITY OF CHATGPT TO ANSWER COMMON PATIENT QUESTIONS ENCOUNTERED BY REPRODUCTIVE UROLOGISTS. Fertility And Sterility 2023, 120: e254. DOI: 10.1016/j.fertnstert.2023.08.714.
1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)McKay R, Xie W, Leucht K, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. 1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC). Annals Of Oncology 2023, 34: s1017-s1018. DOI: 10.1016/j.annonc.2023.09.1122.
1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinomaSaliby R, Jammihal T, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, Zarif T, Ahmar N, Laimon Y, Heng D, Signoretti S, Van Allen E, Choueiri T, Shukla S, Braun D. 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma. Annals Of Oncology 2023, 34: s1017. DOI: 10.1016/j.annonc.2023.09.1121.
Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelinesWang C, Meriggiola M, Amory J, Barratt C, Behre H, Bremner W, Ferlin A, Honig S, Kopa Z, Lo K, Nieschlag E, Page S, Sandlow J, Sitruk‐Ware R, Swerdloff R, Wu F, Goulis D. Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines. Andrology 2023 PMID: 37727884, DOI: 10.1111/andr.13525.
Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic NeoplasmsLabaki C, Al-Choueiry M, Nyman J, Hou Y, Bi K, Zhang L, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Fu J, Camp S, Saliby R, Saad E, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms. The Oncologist 2023, 28: s7-s8. PMCID: PMC10445568, DOI: 10.1093/oncolo/oyad216.011.
Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)Saad E, Labaki C, Saliby R, Bakouny Z, Song L, Wall M, Pan W, Semaan K, Eid M, Gwo-Shu M, Braun D, Liu X, Choueiri T. Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC). The Oncologist 2023, 28: s4-s5. PMCID: PMC10445570, DOI: 10.1093/oncolo/oyad216.007.
Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinomaSaliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. The Oncologist 2023, 28: s15-s16. PMCID: PMC10445571, DOI: 10.1093/oncolo/oyad216.026.
Preferences for Public Health Messaging Related to Bladder Health in Adolescent and Adult WomenBurgio K, Cunningham S, Newman D, Low L, Nodora J, Lipman T, Klusaritz H, James A, Rickey L, Gahagan S, Hebert-Beirne J, Kenton K, Williams B. Preferences for Public Health Messaging Related to Bladder Health in Adolescent and Adult Women. Journal Of Women's Health 2023, 32: 1120-1135. PMID: 37610853, PMCID: PMC10541935, DOI: 10.1089/jwh.2022.0463.
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesSchoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: a013-a013. DOI: 10.1158/1538-7445.kidney23-a013.
Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockadeHugaboom M, Ruthen N, Jegede O, Schindler N, Wirth L, Kyrysyuk S, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D, Street K. Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade. Cancer Research 2023, 83: b013-b013. DOI: 10.1158/1538-7445.kidney23-b013.
Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)Semaan K, Zarif T, Eid M, Shah V, Fortunato B, Saliby R, Nassar A, Alaiwi S, Seo J, Labaki C, Bakouny Z, Matar S, Ahmar N, Laimon Y, Lee G, Pomerantz M, Berchuck J, Signoretti S, Van Allen E, Choueiri T, Braun D, Freedman M, Baca S. Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC). Cancer Research 2023, 83: a029-a029. DOI: 10.1158/1538-7445.kidney23-a029.
Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironmentAlchoueiry M, Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Wells J, Takemura K, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Saliby R, Saad E, Salem S, Daou M, McKay R, Pal S, Heng D, Van Allen E, Shukla S, Choueiri T, Braun D, Henske E. Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment. Cancer Research 2023, 83: b019-b019. DOI: 10.1158/1538-7445.kidney23-b019.
Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: pr015-pr015. DOI: 10.1158/1538-7445.kidney23-pr015.
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrationsŚlusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
Attitudes towards disposition of cryopreserved sperm in the event of death.Buller D, Harnisch B, Lyall V, Goltzman M, Neuber E, Bartolucci A, Honig S. Attitudes towards disposition of cryopreserved sperm in the event of death. Canadian Journal Of Urology 2023, 30: 11613-11618. PMID: 37633289.
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the USKc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell CarcinomaLabaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
Local Therapeutics for the Treatment of Oligo Metastatic Prostate CancerJalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerO'Donnell P, Milowsky M, Petrylak D, Hoimes C, Flaig T, Mar N, Moon H, Friedlander T, McKay R, Bilen M, Srinivas S, Burgess E, Ramamurthy C, George S, Geynisman D, Bracarda S, Borchiellini D, Geoffrois L, Rey J, Ferrario C, Carret A, Yu Y, Guseva M, Moreno B, Rosenberg J. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal Of Clinical Oncology 2023, 41: 4107-4117. PMID: 37369081, PMCID: PMC10852367, DOI: 10.1200/jco.22.02887.
Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture DiseaseSterling J, Rahman S, Varghese A, Angulo J, Nikolavsky D. Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture Disease. Journal Of Clinical Medicine 2023, 12: 3950. PMCID: PMC10299043, DOI: 10.3390/jcm12123950.
Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture DiseaseSterling J, Rahman S, Varghese A, Angulo J, Nikolavsky D. Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture Disease. Journal Of Clinical Medicine 2023, 12: 3950. PMID: 37373644, PMCID: PMC10299043, DOI: 10.3390/jcm12123950.
Crisis of the Clinical Trials Staff Attrition After the COVID-19 PandemicSun G, Dizon D, Szczepanek C, Petrylak D, Sparks D, Tangen C, Lara P, Thompson I, Blanke C. Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. JCO Oncology Practice 2023, 19: 533-535. PMID: 37285550, PMCID: PMC10424897, DOI: 10.1200/op.23.00152.
Machine learning to predict future PSA in patients with prostate cancer managed with active surveillance.Ayed A, Saillard C, Onofrey J, Moon I, Chang S, Feldman A, Nayan M. Machine learning to predict future PSA in patients with prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2023, 41: e17098-e17098. DOI: 10.1200/jco.2023.41.16_suppl.e17098.
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Braun D, Street K, Jegede O, Ruthen N, Hugaboom M, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C. Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study. Journal Of Clinical Oncology 2023, 41: 4524-4524. DOI: 10.1200/jco.2023.41.16_suppl.4524.
Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Labaki C, Bakouny Z, Lemelin A, Ernst M, Takemura K, Wells J, Pal S, Szabados B, Beuselinck B, McKay R, Lee J, Yuasa T, Parnis F, Bjarnason G, McGregor B, Braun D, Xie W, Xu W, Heng D, Choueiri T. Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2023, 41: 4519-4519. DOI: 10.1200/jco.2023.41.16_suppl.4519.
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).McGregor B, Huang J, Xie W, Xu W, Bilen M, Braun D, Zhang T, McKay R, McDermott D, Hammers H, Choueiri T. Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). Journal Of Clinical Oncology 2023, 41: 4520-4520. DOI: 10.1200/jco.2023.41.16_suppl.4520.
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.Saliby R, El Zarif T, Bakouny Z, Xie W, Flippot R, Denize T, Shah V, Kane H, Madsen K, Harshman L, Vaishampayan U, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab. Journal Of Clinical Oncology 2023, 41: 4535-4535. DOI: 10.1200/jco.2023.41.16_suppl.4535.
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.El Ahmar N, Matar S, Jegede O, Savla V, Bagheri Sheshdeh A, Ghandour F, Denize T, West D, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2023, 41: 4549-4549. DOI: 10.1200/jco.2023.41.16_suppl.4549.
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).Saad E, Labaki C, Saliby R, Song L, Bakouny Z, Pan W, Wall M, Lee G, Braun D, Liu X, Choueiri T. Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4550-4550. DOI: 10.1200/jco.2023.41.16_suppl.4550.
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Labaki C, Hobeika C, Hou Y, Zhang L, Bi K, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms. Journal Of Clinical Oncology 2023, 41: 4558-4558. DOI: 10.1200/jco.2023.41.16_suppl.4558.
Trends in new and persistent opioid use in older adults with cancer.Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Leapman M, Jairam V, Dinan M, Lerro C, Woods C, Lee H, Ho A, Graham D, Liberatore M, Rivera D, Gross C, Park H. Trends in new and persistent opioid use in older adults with cancer. Journal Of Clinical Oncology 2023, 41: 1592-1592. DOI: 10.1200/jco.2023.41.16_suppl.1592.
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Gupta S, Rosenberg J, McKay R, Flaig T, Petrylak D, Hoimes C, Friedlander T, Bilen M, Srinivas S, Burgess E, Merchan J, Tagawa S, Brown J, Yu Y, Carret A, Wirtz H, Guseva M, Homet Moreno B, Milowsky M. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. Journal Of Clinical Oncology 2023, 41: 4505-4505. DOI: 10.1200/jco.2023.41.16_suppl.4505.
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).Loriot Y, Petrylak D, Rezazadeh A, Flechon A, Jain R, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthelemy P, Balar A, Tagawa S. Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Journal Of Clinical Oncology 2023, 41: 4514-4514. DOI: 10.1200/jco.2023.41.16_suppl.4514.
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.Friedlander T, Milowsky M, O'Donnell P, Petrylak D, Hoimes C, Flaig T, Mar N, Moon H, McKay R, Bilen M, Borchiellini D, Iafolla M, Carret A, Yu Y, Guseva M, Kataria R, Rosenberg J. Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data. Journal Of Clinical Oncology 2023, 41: 4568-4568. DOI: 10.1200/jco.2023.41.16_suppl.4568.
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Loriot Y, Balar A, Petrylak D, Rezazadeh A, Grivas P, Flechon A, Jain R, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Elboudwarej E, Diehl L, Jürgensmeier J, Tagawa S. Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression. Journal Of Clinical Oncology 2023, 41: 4579-4579. DOI: 10.1200/jco.2023.41.16_suppl.4579.
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.Flaig T, Rosenberg J, Hoimes C, O'Donnell P, Mar N, Gourdin T, Henry S, Bilen M, George S, Barata P, Srinivas S, Rao S, Assikis V, Burgess E, Ramamurthy C, Haas G, Lukas J, Mildiner-Earley S, Yu Y, Petrylak D. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. Journal Of Clinical Oncology 2023, 41: 4595-4595. DOI: 10.1200/jco.2023.41.16_suppl.4595.
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Sadeghi S, Plets M, Lara P, Tangen C, Bangs R, Lerner S, Flaig T, Petrylak D, Thompson I. A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. Journal Of Clinical Oncology 2023, 41: tps4608-tps4608. DOI: 10.1200/jco.2023.41.16_suppl.tps4608.
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.Aggarwal R, Zhang J, Monk P, Zhu X, Costin D, Petrylak D, Borderies P, Deshpande R, Hafeez A, O'Neill V, Tagawa S. First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial. Journal Of Clinical Oncology 2023, 41: tps5109-tps5109. DOI: 10.1200/jco.2023.41.16_suppl.tps5109.
Male Reproduction in the Transgender PatientHarnisch B, Honig S. Male Reproduction in the Transgender Patient. 2023, 525-533. DOI: 10.1017/9781108937054.032.
Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone CompositionSimmons K, Nair H, Phadke M, Motamedinia P, Singh D, Montgomery T, Dahl N. Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition. American Journal Of Nephrology 2023, 54: 329-336. PMID: 37253348, DOI: 10.1159/000531046.
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyGhali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.
(394) Effects of Age, Body Mass Index (BMI) and Diabetic Status on Testosterone Levels, Testosterone Dosing and Safety in Hypogonadal Men Treated with an Oral Testosterone Undecanoate (JATENZO)Honig S, Swerdloff R, Wang C, Rohowsky N, Newmark J, Seo B, Dudley R. (394) Effects of Age, Body Mass Index (BMI) and Diabetic Status on Testosterone Levels, Testosterone Dosing and Safety in Hypogonadal Men Treated with an Oral Testosterone Undecanoate (JATENZO). The Journal Of Sexual Medicine 2023, 20 DOI: 10.1093/jsxmed/qdad060.368.
DuSFE: Dual-Channel Squeeze-Fusion-Excitation co-attention for cross-modality registration of cardiac SPECT and CTChen X, Zhou B, Xie H, Guo X, Zhang J, Duncan J, Miller E, Sinusas A, Onofrey J, Liu C. DuSFE: Dual-Channel Squeeze-Fusion-Excitation co-attention for cross-modality registration of cardiac SPECT and CT. Medical Image Analysis 2023, 88: 102840. PMID: 37216735, PMCID: PMC10524650, DOI: 10.1016/j.media.2023.102840.
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESArmstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. European Urology 2023, 84: 229-241. PMID: 37179240, DOI: 10.1016/j.eururo.2023.04.002.
Negotiating Toilet Access: A Qualitative Exploration of Women's IncarcerationSmoyer A, Schwarz P, Camenga D, Rickey L. Negotiating Toilet Access: A Qualitative Exploration of Women's Incarceration. The Prison Journal 2023, 103: 329-346. DOI: 10.1177/00328855231173146.
Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learningKucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning. Scientific Reports 2023, 13: 7579. PMID: 37165035, PMCID: PMC10172370, DOI: 10.1038/s41598-023-34439-7.
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeuticsLokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinomaChow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialGrivas P, Park S, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar S, Yamamoto Y, Petrylak D, Sternberg C, Gupta S, Huang B, Costa N, Laliberte R, di Pietro A, Valderrama B, Powles T. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. European Urology 2023, 84: 95-108. PMID: 37121850, DOI: 10.1016/j.eururo.2023.03.030.
Spontaneous vesicoureteral reflux resolution curves based on ureteral diameter ratioArlen A, Leong T, Kirsch A, Cooper C. Spontaneous vesicoureteral reflux resolution curves based on ureteral diameter ratio. Journal Of Pediatric Urology 2023, 19: 468.e1-468.e6. PMID: 37188603, DOI: 10.1016/j.jpurol.2023.04.028.
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. European Urology Oncology 2023, 6: 516-524. PMID: 37087309, PMCID: PMC10587361, DOI: 10.1016/j.euo.2023.03.008.
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsAntonarakis E, Subudhi S, Pieczonka C, Karsh L, Quinn D, Hafron J, Wilfehrt H, Harmon M, Sheikh N, Shore N, Petrylak D. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research 2023, 29: 2426-2434. PMID: 37058234, PMCID: PMC10320463, DOI: 10.1158/1078-0432.ccr-22-3832.
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerHalabi S, Yang Q, Roy A, Luo B, Araujo J, Logothetis C, Sternberg C, Armstrong A, Carducci M, Chi K, de Bono J, Petrylak D, Fizazi K, Higano C, Morris M, Rathkopf D, Saad F, Ryan C, Small E, Kelly W. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal Of Clinical Oncology 2023, 41: 2736-2746. PMID: 37040594, PMCID: PMC10414709, DOI: 10.1200/jco.22.02661.
The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and OpportunitiesGhali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.
Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Cancer Research 2023, 83: 3287-3287. DOI: 10.1158/1538-7445.am2023-3287.
PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNINGEsmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASETLeapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGELeapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCERLeapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.

Download Full List